(Z)-Lanoconazole is the Z configuration of Lanoconazole, used for investigating dermatophytosis and onychomycosis. It inhibits sterol 14-alpha demethylase, disrupting fungal membrane ergosterol biosynthesis. Lanoconazole is a potent, orally active imidazole antifungal agent with a broad spectrum of activity against fungi both in vitro and in vivo [1] [2].

Lanoconazole effectively mitigates TPA-induced irritant dermatitis through a dose-dependent mechanism (treatment applied to the ear; concentrations between 0.3%-3%; over 6 days), by reducing the production of neutrophil chemotactic factors, including keratinocyte-derived chemokine and macrophage inflammatory protein-2, and by inhibiting neutrophil migration to the site of inflammation [2]. Furthermore, when administered orally at doses of 3, 10, or 30 mg/kg once daily for three weeks, lanoconazole significantly hampers the growth of C. neoformans in comparison to a saline control in healthy mice. It also notably decreases the proliferation of C. neoformans in the lungs and brains of MAIDS mice, demonstrating its potent antifungal efficacy [3].